Hoping to cut into the dominance of Dupixent, Leo Pharma of Denmark has gained FDA approval for Adbry (tralokinumab) as a treatment for moderate to severe atopic dermatitis.
The injected antibody drug is for adults 18 and older who don
Found this useful? Share it with your team.
